Pharmacogenetic and Pharmacokinetic Factors for Dexmedetomidine-associated Hemodynamic Instability in Pediatric Patients

Overview

Journal Front Pharmacol

Date 2025 Jan 22

PMID 39840108

Authors

Yanping Guan

Bilian Li

Yiyu Zhang

Hao Luo

Xueding Wang

Xue Bai

Zhuoling Zheng

Yaying Huang

Wei Wei

Min Huang

Xingrong Song

Guoping Zhong

Affiliations

Soon will be listed here.

Abstract

Purpose: The incidence of hemodynamic instability associated with dexmedetomidine (DEX) sedation has been reported to exceed 50%, with substantial inter-individual variability in response. Genetic factors have been suggested to contribute significantly to such variation. The aim of this study was to identify the clinical, pharmacokinetic, and genetic factors associated with DEX-induced hemodynamic instability in pediatric anesthesia patients.

Methods: A cohort of 270 pediatric patients scheduled for elective interventional surgery received an intranasal dose of 3 mcg·kg of dexmedetomidine, and subsequent propofol induction was conducted when patients had a UMSS of 2-4. The primary endpoint was hemodynamic instability-defined as a composite of hypotension and/or bradycardia, which is characterized by a 20% reduction from age-specific baseline values. Plasma concentrations of dexmedetomidine were determined, and single-nucleotide polymorphisms (SNPs) were genotyped. A validated population pharmacokinetic model was used to estimate pharmacokinetic parameters. LASSO regression was used to identify significant factors, and a Cox's proportional hazards model-derived nomogram for hemodynamic instability was developed.

Results: Hemodynamic instability was observed in 52 out of 270 patients (209 events), resulting in a cumulative incidence of 16.30% at 90 min, as estimated by Kaplan-Meier estimation, and it was associated with a median time to event of 35 min. The interval time between DEX initiation and propofol induction was 16 min (IQR: 12-22 min). The cumulative incidence was 8.2% within 22 min after DEX initiation. The identified significant risk factors for DEX-associated hemodynamic instability included weight, DEX clearance, concomitant propofol use, and the following gene variants rs1841042 (hazard ratio (HR):1.41, 95% confidence interval (CI): 1.12-1.79), rs8192733 (HR:0.28, 95%CI:0.09-0.88), rs3813662 (HR:1.39,95%CI:1.02-1.89), rs2236957 (HR:1.46, 95%CI:1.09-1.96), rs3814057 (HR:0.64, 95%CI:0.43-0.95), and rs10764319 (HR:1.40,95%CI:1.05-1.87). The areas under the curve for the training and test cohorts were 0.881 and 0.762, respectively. The calibration curve indicated excellent agreement.

Conclusion: The predictive nomogram, which incorporates genetic variants (, and ) along with clinical factors such as weight, DEX clearance, and propofol use, may help prevent DEX-associated hemodynamic instability. Delayed hemodynamic instability is likely to occur after 35-min DEX initiation in patients with lower DEX clearance after propofol induction.

References

Kohli U, Pandharipande P, Muszkat M, Sofowora G, Friedman E, Scheinin M . CYP2A6 genetic variation and dexmedetomidine disposition. Eur J Clin Pharmacol. 2012; 68(6):937-42. PMC: 3352974. DOI: 10.1007/s00228-011-1208-z. View

Lu N, Yuan Y, Piao J, Pei F, Sun K, Zheng Y . Association between Common Genetic Variants of α2A-, α2B-, and α2C-Adrenergic Receptors and Orthostatic Hypotension. Clin Lab. 2015; 61(8):1033-41. DOI: 10.7754/clin.lab.2015.150107. View

Scholl U, Goh G, Stolting G, de Oliveira R, Choi M, Overton J . Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet. 2013; 45(9):1050-4. PMC: 3876926. DOI: 10.1038/ng.2695. View

Carter B, Long T, Cinciripini P . A meta-analytic review of the CYP2A6 genotype and smoking behavior. Nicotine Tob Res. 2004; 6(2):221-7. DOI: 10.1080/14622200410001676387. View

Moosmang S, Schulla V, Welling A, Feil R, Feil S, Wegener J . Dominant role of smooth muscle L-type calcium channel Cav1.2 for blood pressure regulation. EMBO J. 2003; 22(22):6027-34. PMC: 275441. DOI: 10.1093/emboj/cdg583. View

Murakami M, Yamamura H, Murakami A, Okamura T, Nunoki K, Muraki K . Conserved smooth muscle contractility and blood pressure increase in response to high-salt diet in mice lacking the beta3 subunit of the voltage-dependent calcium channel. J Cardiovasc Pharmacol. 2001; 36 Suppl 2:S69-73. DOI: 10.1097/00005344-200000006-00015. View

Bulow N, Colpo E, Pereira R, Correa E, Waczuk E, Duarte M . Dexmedetomidine decreases the inflammatory response to myocardial surgery under mini-cardiopulmonary bypass. Braz J Med Biol Res. 2016; 49(4):e4646. PMC: 4792505. DOI: 10.1590/1414-431X20154646. View

Wang L, Wang S, Qi J, Yu R, Zhuang J, Zhuang B . Impact of CYP2A6 gene polymorphism on the pharmacokinetics of dexmedetomidine for premedication. Expert Rev Clin Pharmacol. 2018; 11(9):917-922. DOI: 10.1080/17512433.2018.1510312. View

Holliday S, Kane-Gill S, Empey P, Buckley M, Smithburger P . Interpatient variability in dexmedetomidine response: a survey of the literature. ScientificWorldJournal. 2014; 2014:805013. PMC: 3914598. DOI: 10.1155/2014/805013. View

10.

Parkinson N, Hughes A . The mechanism of action of alpha 2-adrenoceptors in human isolated subcutaneous resistance arteries. Br J Pharmacol. 1995; 115(8):1463-8. PMC: 1908876. DOI: 10.1111/j.1476-5381.1995.tb16638.x. View

11.

Mason K, Lerman J . Review article: Dexmedetomidine in children: current knowledge and future applications. Anesth Analg. 2011; 113(5):1129-42. DOI: 10.1213/ANE.0b013e31822b8629. View

12.

Scheinin M, Schwinn D . The locus coeruleus. Site of hypnotic actions of alpha 2-adrenoceptor agonists?. Anesthesiology. 1992; 76(6):873-5. DOI: 10.1097/00000542-199206000-00001. View

13.

Blin N, Stafford D . A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res. 1976; 3(9):2303-8. PMC: 343085. DOI: 10.1093/nar/3.9.2303. View

14.

Chatzistefanidis D, Georgiou I, Kyritsis A, Markoula S . Functional impact and prevalence of polymorphisms involved in the hepatic glucuronidation of valproic acid. Pharmacogenomics. 2012; 13(9):1055-71. DOI: 10.2217/pgs.12.78. View

15.

Raunio H, Rautio A, Gullsten H, Pelkonen O . Polymorphisms of CYP2A6 and its practical consequences. Br J Clin Pharmacol. 2001; 52(4):357-63. PMC: 2014580. DOI: 10.1046/j.0306-5251.2001.01500.x. View

16.

Dennhardt N, Beck C, Huber D, Sander B, Boehne M, Boethig D . Optimized preoperative fasting times decrease ketone body concentration and stabilize mean arterial blood pressure during induction of anesthesia in children younger than 36 months: a prospective observational cohort study. Paediatr Anaesth. 2016; 26(8):838-43. DOI: 10.1111/pan.12943. View

17.

Kaivosaari S, Toivonen P, Aitio O, Sipila J, Koskinen M, Salonen J . Regio- and stereospecific N-glucuronidation of medetomidine: the differences between UDP glucuronosyltransferase (UGT) 1A4 and UGT2B10 account for the complex kinetics of human liver microsomes. Drug Metab Dispos. 2008; 36(8):1529-37. DOI: 10.1124/dmd.108.021709. View

18.

Okello M, Mungayi V, Adam R, Kabugi J . A comparison of risk of hypotension using standard doses of remifentanil versus dexmedetomidine infusions in adult patients undergoing surgery under general anaesthesia at the Aga Khan University Hospital, Nairobi. Afr Health Sci. 2019; 18(4):1267-1282. PMC: 6354876. DOI: 10.4314/ahs.v18i4.48. View

19.

Mahmoud M, Mason K . Dexmedetomidine: review, update, and future considerations of paediatric perioperative and periprocedural applications and limitations. Br J Anaesth. 2015; 115(2):171-82. DOI: 10.1093/bja/aev226. View

20.

Kaur M, Singh P . Current role of dexmedetomidine in clinical anesthesia and intensive care. Anesth Essays Res. 2015; 5(2):128-33. PMC: 4173414. DOI: 10.4103/0259-1162.94750. View